Hypertropic Cardiomyopathy Models
Obesity ModelsDiabetes ModelsAndrogenetic Alopecia (AGA) ModelsMASH ModelsChronic Liver Fibrosis ModelsAcute Liver Injury ModelsChronic Kindey Disease (CKD) ModelsCholestasis ModelsAlcohol-related Liver Disease (ALD) ModelsActue Kindey Disease (AKD) ModelsDiabetes Nephropathy (Diabetic Kidney Disease) ModelsOsteoporosis ModelsSarcopenia ModelsGout/Hyperuricemia ModelsFemale Reproduction Models
Hemophilia ModelsProgressive Familial Intrahepatic Cholestasis ModelsAutosomal Dominant Polycystic Kidney Disease (ADPKD)Glycogen Storage Disease type 1a ModelGrowth Failure ModelsFabry Disease ModelsHepatolenticular Degeneration ModelNiemann-Pick Disease (Sphingomyelinosis) ModelsHypophosphatasia ModelGM2 Gangliosidoses ModelPulmonary Alveolar Proteinosis ModelLimb Girdle Muscular Dystrophies ModelMaple Syrup Urine Disease ModelMucopolysaccharidosis ModelsHutchinson-Gilford Progeria Syndrome ModelPhenylketonuria/Hyperphenylalaninemia ModelsUrea Cycle Disorders ModelsTyrosinemia ModelThalassemia Models
Hypertrophic cardiomyopathy (HCM) is a common yet complex genetic heart disorder, which is characterized by hypertrophy of the heart muscle, most commonly affecting the left ventricle. Mutations in genes encoding or related to cardiac sarcomere proteins, such as MYBPC3, MYH7, and TNNT2, can be introduced into animals via gene editing. These mutations disrupt the normal structure and function of the heart muscle, leading to the development of HCM. GemPharmatech has developed Myh6 R404Q and Mybpc3 KO mouse models which express hypertrophic cardiomyopathy phenotypes and can provide drug efficacy evaluation services based on these models.